ViewRay Company Profile (NASDAQ:VRAY)

ViewRay trades on the NASDAQ under the ticker symbol "VRAY."

ViewRay, Inc. (NASDAQ:VRAY) posted its quarterly earnings results on Monday, May, 15th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.22) by $0.02. The company earned $1.23 million during the quarter, compared to analyst estimates of $0.52 million. The company's quarterly revenue was down 77.5% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.35) earnings per share. View ViewRay's Earnings History.

4 analysts have issued 12 month price targets for ViewRay's shares. Their forecasts range from $7.00 to $11.00. On average, they anticipate ViewRay's stock price to reach $9.50 in the next twelve months. View Analyst Ratings for ViewRay.

Here are some recent quotes from research analysts about ViewRay stock:

• 1. Northland Securities analysts commented, "We are maintaining our FY17 & FY18 numbers, and our PT & ratings remain the same. Key Points Perhaps the most interesting takeaway from the call was the announcement of a multi-institutional trial on unresectable pancreatic cancer using MRIdian. It is our understanding that this trial will include both MRIdian Cobalt & LINAC (as they become available); will include a hard endpoint like survival, and possibly" intraop dose titration and impact on outcomes. As a reminder, most patients with pancreatic cancer will die within 1 – 2 years, with median survival @ 1-year. Hence, it is certainly possible that ViewRay could provide survival endpoints for such a trial in late 2018 / early 2019. This obviously is predicated on the trial design, sample size, inclusion criteria, and whether this will be randomized or not. The ideal design would obviously be to include a comparative arm with another RT machine (like the TruBeam) & compare to MRIdian. Finally, how outcomes will be influenced with the use of Cobalt vs. LINAC will also be interesting to note, although it might be hard to draw any statistical conclusions given small sample size." (5/16/2017)
• 2. Aegis analysts commented, "We are assuming coverage of VRAY with a Buy rating and $11 PT. We believe the MRI-guided LINAC is a game-changer in radiation oncology, with real-time imaging improving dosimetry and reducing the toxicity to patients. The combination improves functionality and expands the use of stereotactic body radiation therapy (SBRT), and physicians believe the system can expand the total treatable tumors by at least 20%." (5/16/2017)
• 3. BTIG Research analysts commented, "While we admit the higher price per system may impact how many hospitals will ultimately adopt, we feel the early adopters who are less price sensitive will drive strong initial orders and the stock over the next few years."If properly marketed, patients will learn about live imaging and, we believe, seek out centers with its availability. We are not calling for ISRG like success this early but could envision a similar hospital arms race," (9/14/2016)

Some companies that are related to ViewRay include LeMaitre Vascular (LMAT), Accuray Incorporated (ARAY), Pacific Biosciences of California (PACB), Corindus Vascular Robotics (CVRS), Cytosorbents Corporation (CTSO), Alliance HealthCare Services (AIQ), Viveve Medical (VIVE), Fulgent Genetic (FLGT), IRIDEX Corporation (IRIX), Cogentix Medical (CGNT), Neovasc Inc (US) (NVCN), EDAP TMS S.A. (EDAP), Harvard Bioscience (HBIO), Digirad Corporation (DRAD), Biolase (BIOL), Electromed (ELMD), Presbia PLC (LENS) and EnteroMedics (ETRM).

(VRAY) raised $52 million in an initial public offering on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

Shares of ViewRay can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ViewRay stock can currently be purchased for approximately $5.17.